Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 12/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | GALR3 | O60755 | 1/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13624224 | 0.85 | MAPT (0.48) | MAPTALDH1A1SMN1; SMN2LMNANPC1 | |
| SCHEMBL25845895 | 0.79 | MAPT (0.78) | MAPTALDH1A1SMN1; SMN2LMNAMAPK1 | |
| SCHEMBL17630429 | 0.78 | AKR1C3 (0.51) | MAPTALDH1A1MAPK1AKR1C3TDP1 | |
| SCHEMBL16569899 | 0.76 | MAPT (0.58) | MAPTALDH1A1SMN1; SMN2LMNAMAPK1 | |
| SCHEMBL27464372 | 0.74 | MAPT (0.79) | MAPTALDH1A1SMN1; SMN2LMNAHTT | |
| SCHEMBL31438048 | 0.74 | MEN1 (0.50) | MAPTALDH1A1SMN1; SMN2LMNAMAPK1 | |
| SCHEMBL14241535 | 0.72 | SIRT6 (0.53) | MAPTALDH1A1LMNARAB9AAKR1C3 | |
| SCHEMBL17630536 | 0.71 | SIRT6 (0.49) | MAPTALDH1A1MAPK1AKR1C3TDP1 | |
| SCHEMBL17630533 | 0.71 | SIRT6 (0.49) | MAPTALDH1A1MAPK1AKR1C3TDP1 | |
| SCHEMBL3568725 | 0.70 | MAPT (0.64) | MAPTALDH1A1SMN1; SMN2LMNAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090291945-A1 | CYSTEINE PROTEASE INHIBITORS | TEIJIN PHARMA LIMITED (JP) | 2009-11-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090291945-A1 | CYSTEINE PROTEASE INHIBITORS | CTSE, SPINT2, CTSF | MAPT 480/4885ALDH1A1 2506/4885SMN1; SMN2 4525/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.